An open‐label, dose‐escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension

Preclinical and early clinical studies suggest that angiotensin‐converting enzyme type 2 activity may be impaired in patients with pulmonary arterial hypertension (PAH); therefore, administration of exogenous angiotensin‐converting enzyme type 2 (ACE2) may be beneficial. This Phase IIa, multi‐center...

Descripción completa

Detalles Bibliográficos
Autores principales: Simon, Marc A., Hanrott, Kate, Budd, David C., Torres, Fernando, Grünig, Ekkehard, Escribano‐Subias, Pilar, Meseguer, Manuel L., Halank, Michael, Opitz, Christian, Hall, David A., Hewens, Deborah, Powley, William M., Siederer, Sarah, Bayliffe, Andrew, Lazaar, Aili L., Cahn, Anthony, Rosenkranz, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9053011/
https://www.ncbi.nlm.nih.gov/pubmed/35506108
http://dx.doi.org/10.1002/pul2.12024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9053011/
https://www.ncbi.nlm.nih.gov/pubmed/35506108
http://dx.doi.org/10.1002/pul2.12024

Ejemplares similares